Studying IBI363 combo for advanced colorectal cancer
Part of Cancer, Immune system & allergy clinical trials.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that is pMMR, MSI-L, or MSS (these are types of tumor characteristics).
- You are between 18 and 75 years old.
- You do not have active or untreated brain metastases.
- You do not have serious heart or lung problems (like heart failure, recent heart attack, or lung scarring).
- You do not have active liver metastases (unless they were treated and gone for at least 6 months).
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
This study looks at how well different combinations of immunotherapy drugs work for advanced colorectal cancer that is MSS or MSI-L or pMMR. It reviews past patient records to see which treatments help control the disease and slow its growth.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.